It’s been just reported that cancer patients may have a ray of light to cling on. We are talking about high-risk melanoma patients. Check out the latest exciting reports that have been just revealed.
New cancer vaccine on the way?
CNBC just noted that Moderna and Merck would jointly develop and sell a cancer vaccine that is personalized for individual patients, the companies announced on Wednesday.
“Moderna’s vaccine, based on its messenger RNA technology, is being studied in combination with Merck’s Keytruda to treat patients with high-risk melanoma, the deadliest form of skin cancer, in a phase 2 trial. The companies expect to report data in the fourth quarter of this year,” according to CNBC.
Moderna’s stock jumped 16% in morning trading following the news, and this is great for the company.
As you probably know by now, the firm has been making a lot of headlines due to the covid vaccine that it developed.
Moderna and Merck in the news
Back in March, we were revealing that Moderna CEO Stephane Bancel has sold $408 million in company stock since the beginning of the coronavirus pandemic. This is reportedly averaging roughly $3.6 million a week — as the company’s stock soared on the development and rollout of its Covid vaccine, according to CNBC’s analysis of the company’s securities filings.
As for Merck, we addressed the company last year.
Besides the covid 19 vaccines that have already been deployed worldwide, experts everywhere are making great efforts to find a cure for covid as well.
There are multiple treatments that are being analyzed these days, and we’ll be addressing the one that Merck and AstraZeneca are working on.
Merck teamed up with partner Ridgeback Biotherapeutics, and has already said the following:
“data from a Phase 3 trial of the treatment, molnupiravir, an oral antiviral medicine, reduced the risk of hospitalization or death in adults at risk from severe covid 19 by 50%.”
As you definitely know by now, there are various effective vaccines that have been developed against the illness, but, on the other hand, far fewer treatments have emerged, and those that have “require infusions and must be administered in a clinical setting,” as the same online publication notes.
“Molnupiravir is a pill administered orally in capsule form every 12 hours for five days, according to clinicaltrials.gov.”
Stay tuned for more news.
